| Jason M Robke, MD | |
|
3600 Kolbe Rd Ste 210, Lorain, OH 44053-1652 | |
| (440) 222-4567 | |
| (440) 960-6435 |
| Full Name | Jason M Robke |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 27 Years |
| Location | 3600 Kolbe Rd Ste 210, Lorain, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841218955 | NPI | - | NPPES |
| 7042623 | Other | AETNA | |
| 363959 | Other | WELLCARE | |
| 000000221224 | Other | UNISON | |
| 000000503668 | Other | ANTHEM | |
| 741760 | Other | BUCKEYE | |
| 2495205 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 35-084902 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Frmc Home Health Services | Sandusky, OH | Home health agency |
| Mercy Regional Medical Center | Lorain, OH | Hospital |
| Firelands Regional Medical Center | Sandusky, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Health Physicians Lorain Specialty Care Llc | 4688070055 | 119 |
News Archive
Our understanding of the importance of microRNAs in regulating gene expression is expanding, and with it our requirement for robust methods to measure their expression levels. Now a new method published in BioMed Central's open access journal Genome Biology helps researchers to better understand the delicate interplay between differences in microRNA expression levels and their target genes.
Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.
At the National Patient Safety Foundation Congress beginning today in Washington, D.C., two leaders in their respective healthcare areas have joined forces to improve patient safety.
Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
› Verified 9 days ago
| Entity Name | Mercy Health Physicians Lorain Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023347192 PECOS PAC ID: 1355474172 Enrollment ID: O20100730000651 |
News Archive
Our understanding of the importance of microRNAs in regulating gene expression is expanding, and with it our requirement for robust methods to measure their expression levels. Now a new method published in BioMed Central's open access journal Genome Biology helps researchers to better understand the delicate interplay between differences in microRNA expression levels and their target genes.
Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.
At the National Patient Safety Foundation Congress beginning today in Washington, D.C., two leaders in their respective healthcare areas have joined forces to improve patient safety.
Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
› Verified 9 days ago
| Entity Name | Mercy Health Physicians Lorain Specialty Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972126381 PECOS PAC ID: 4688070055 Enrollment ID: O20210909003432 |
News Archive
Our understanding of the importance of microRNAs in regulating gene expression is expanding, and with it our requirement for robust methods to measure their expression levels. Now a new method published in BioMed Central's open access journal Genome Biology helps researchers to better understand the delicate interplay between differences in microRNA expression levels and their target genes.
Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.
At the National Patient Safety Foundation Congress beginning today in Washington, D.C., two leaders in their respective healthcare areas have joined forces to improve patient safety.
Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jason M Robke, MD 3600 Kolbe Rd Ste 210, Lorain, OH 44053-1652 Ph: (440) 222-4567 | Jason M Robke, MD 3600 Kolbe Rd Ste 210, Lorain, OH 44053-1652 Ph: (440) 222-4567 |
News Archive
Our understanding of the importance of microRNAs in regulating gene expression is expanding, and with it our requirement for robust methods to measure their expression levels. Now a new method published in BioMed Central's open access journal Genome Biology helps researchers to better understand the delicate interplay between differences in microRNA expression levels and their target genes.
Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.
At the National Patient Safety Foundation Congress beginning today in Washington, D.C., two leaders in their respective healthcare areas have joined forces to improve patient safety.
Repligen Corporation announced today that it has filed an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) for a Phase 1 study of RG2833, a selective histone deacetylase 3 (HDAC-3) inhibitor. This is a double-blind, single ascending dose, Phase 1 study in healthy volunteers to evaluate the pharmacokinetic and safety profile of RG2833 in up to 40 subjects.
InterMune, Inc. today announced the pricing of its underwritten public offering of 7,000,000 shares of newly issued common stock at a price to the public of $14.10 per share.
› Verified 9 days ago
Alexander Francis Zolli, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 2173 N Ridge Rd E, Suite A, Lorain, OH 44055 Phone: 440-277-5077 Fax: 440-277-6696 | |
Haysam M El Dalati, MD Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 3600 Kolbe Rd, Suite 227, Lorain, OH 44053 Phone: 440-960-3304 Fax: 440-960-3482 |